Search

Your search keyword '"Siccardi, Marco"' showing total 13 results
Start Over Author "Siccardi, Marco" Journal therapeutic drug monitoring
13 results on '"Siccardi, Marco"'

3. Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment

Author

D'Avolio, Antonio, primary, Ciancio, Alessia, additional, Siccardi, Marco, additional, Smedile, Antonina, additional, Simiele, Marco, additional, Cusato, Jessica, additional, Baietto, Lorena, additional, Marucco, Diego Aguilar, additional, Cariti, Giuseppe, additional, Calcagno, Andrea, additional, Gonzalez de Requena, Daniel, additional, Sciandra, Mauro, additional, Troshina, Giulia, additional, Caviglia, Gian Paolo, additional, Bonora, Stefano, additional, Rizzetto, Mario, additional, and Di Perri, Giovanni, additional

Published
2012
Full Text
View/download PDF

4. Prophylactic Drug Monitoring of Itraconazole in an Oncohematological Pediatric Patient Population

Author

Baietto, Lorena, primary, G. De Rosa, Francesco, additional, D'Avolio, Antonio, additional, Marra, Cristina, additional, Pace, Simone, additional, Biasin, Eleonora, additional, Carraro, Francesca, additional, Nesi, Francesca, additional, Simiele, Marco, additional, Cusato, Jessica, additional, Siccardi, Marco, additional, and Di Perri, Giovanni, additional

Published
2012
Full Text
View/download PDF

5. Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting

Author

Siccardi, Marco, primary, D'Avolio, Antonio, additional, Rodriguez-Novoa, Sonia, additional, Cuenca, Lorena, additional, Simiele, Marco, additional, Baietto, Lorena, additional, Calcagno, Andrea, additional, Moss, Darren, additional, Bonora, Stefano, additional, Soriano, Vicente, additional, Back, David J., additional, Owen, Andrew, additional, and Perri, Giovanni Di, additional

Published
2012
Full Text
View/download PDF

6. Inosine Triphosphatase Polymorphisms and Ribavirin Pharmacokinetics as Determinants of Ribavirin-Associate Anemia in Patients Receiving Standard Anti-HCV Treatment

Author

D'Avolio, Antonio, primary, Ciancio, Alessia, additional, Siccardi, Marco, additional, Smedile, Antonina, additional, Baietto, Lorena, additional, Simiele, Marco, additional, Marucco, Diego Aguilar, additional, Cariti, Giuseppe, additional, Calcagno, Andrea, additional, de Requena, Daniel Gonzalez, additional, Sciandra, Mauro, additional, Cusato, Jessica, additional, Troshina, Giulia, additional, Bonora, Stefano, additional, Rizzetto, Mario, additional, and Di Perri, Giovanni, additional

Published
2012
Full Text
View/download PDF

9. An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients

Author

D'Avolio, Antonio, primary, Baietto, Lorena, additional, Siccardi, Marco, additional, Sciandra, Mauro, additional, Simiele, Marco, additional, Oddone, Valentina, additional, Bonora, Stefano, additional, and Perri, Giovanni Di, additional

Published
2008
Full Text
View/download PDF

11. CYP2B6516G>T (rs3745274) and Smoking Status Are Associated With Efavirenz Plasma Concentration in a Serbian Cohort of HIV Patients

Author

Olagunju, Adeniyi, Siccardi, Marco, Amara, Alieu, Jevtovic, Djordje, Kusic, Jovana, Owen, Andrew, and Dragovic, Gordana

Abstract

Genetic factors have been associated with efavirenz (EFV) plasma concentrations in different populations. In this study, we investigated the effects of CYP2B6516G>T (rs3745274), CYP2B6c.485-18C>T (rs4803419), CARc.540C>T (rs2307424), CARc.152-1089T>C (rs3003596), and smoking status in a cohort of Serbian patients with HIV.

Published
2014
Full Text
View/download PDF

12. Negative Predictive Value of IL28B, SLC28A2, and CYP27B1SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEGIFN-RBV Treatment

Author

D'Avolio, Antonio, Ciancio, Alessia, Siccardi, Marco, Smedile, Antonina, Simiele, Marco, Cusato, Jessica, Baietto, Lorena, Marucco, Diego Aguilar, Cariti, Giuseppe, Calcagno, Andrea, Gonzalez de Requena, Daniel, Sciandra, Mauro, Troshina, Giulia, Caviglia, Gian Paolo, Bonora, Stefano, Rizzetto, Mario, and Di Perri, Giovanni

Abstract

The response rate to treatment of chronic hepatitis C virus-genotype 1 and 4 infections was recently found to be strongly influenced by many polymorphisms. The aim of our study was to carry out an integrated analysis of the effects of polymorphisms and ribavirin (RBV) plasma exposure on outcome.

Published
2012
Full Text
View/download PDF

13. Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment.

Author

DʼAvolio A, Ciancio A, Siccardi M, Smedile A, Baietto L, Simiele M, Marucco DA, Cariti G, Calcagno A, de Requena DG, Sciandra M, Cusato J, Troshina G, Bonora S, Rizzetto M, and Di Perri G

Subjects
Adult, Alleles, Anemia, Hemolytic chemically induced, Antiviral Agents adverse effects, Antiviral Agents therapeutic use, Feasibility Studies, Female, Genotype, Hemoglobins metabolism, Humans, Interferon alpha-2, Interferon-alpha administration & dosage, Interferon-alpha therapeutic use, Logistic Models, Male, Middle Aged, Multivariate Analysis, Polyethylene Glycols administration & dosage, Polyethylene Glycols therapeutic use, Polymorphism, Single Nucleotide, Recombinant Proteins administration & dosage, Recombinant Proteins therapeutic use, Retrospective Studies, Ribavirin adverse effects, Ribavirin therapeutic use, Inosine Triphosphatase, Antiviral Agents pharmacokinetics, Hepatitis C drug therapy, Pyrophosphatases genetics, Ribavirin pharmacokinetics
Abstract

Background: Functional variants of inosine triphosphatase (ITPA) were recently found to protect against ribavirin (RBV)-induced hemolytic anemia. However, no definitive data are yet available on the role of plasma RBV concentrations on hemoglobin (Hb) decrement. Moreover, no data have been published on the possible interplay between these 2 factors., Methods: A retrospective analysis included 167 patients. The ITPA variants rs7270101 and rs1127354 were genotyped and tested using the χ test for association with Hb reduction at week 4. We also investigated, using multivariate logistic regression, the impact of RBV plasma exposure on Hb concentrations., Results: Both single nucleotide polymorphisms were associated with Hb decrease. The carrier of at least 1 variant allele in the functional ITPA single nucleotide polymorphisms was associated with a lower decrement of Hb (-1.1 g/dL), as compared with patients without a variant allele (-2.75 g/dL; P = 4.09 × 10). RBV concentrations were not influenced by ITPA genotypes. A cut-off of 2.3 μg/mL of RBV was found to be associated with anemia (area-under-receiver operating characteristic = 0.630, sensitivity = 50.0%, and specificity = 69.5%, P = 0.008). In multivariate logistic regression analyses, the carrier of a variant allele (P = 0.005) and plasma RBV concentrations <2.3 μg/mL (P = 0.016) were independently associated with protection against clinically significant anemia at week 4., Conclusions: Although no direct relationship was found between ITPA polymorphisms and plasma RBV concentrations, both factors were shown to be significantly associated with anemia. A multivariate regression model based on ITPA genetic polymorphisms and RBV trough concentration was developed for predicting the risk of anemia. By relying upon these 2 variables, an individualized management of anemia seems to be feasible in recipients of pegylated interferon-RBV therapy.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results